SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY. (12th June 2019)